Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.
New research demonstrated that, in rhesus monkeys, ongoing cocaine exposure weakens two brain functions that people require for successful behavioral change: cognitive flexibility and memory. But the study determined that these changes may not be permanent.
Clinical trials of N-acetylcysteine to help people recovering from drug abuse avoid relapse have demonstrated only moderate efficacy. New NIDA-supported research shows that while a low dose of the medication activates receptors associated with lowered drug-seeking behavior, a higher dose appears to activate receptors associated with increased drug-seeking behavior. The result suggests that a medication or combination of medications that stimulate the receptor GluR2/3 and block mGluR5 may work better than N-acetylcysteine alone.
The immune system has an extraordinary ability to recognize compounds foreign to the body and eliminate them. NIDA-sponsored scientists are working to harness this ability to create vaccines that will protect individuals against the psychogenic and addictive effects of abused drugs. This animation shows one of the most promising strategies, which has already yielded partial success in producing effective vaccines against nicotine, cocaine, and other drugs.
julio del 2012 Dr. J. David Jentsch is the recipient of the 2011 Jacob P. Waletzky Memorial Award for Innovative Research in Drug Addiction and Alcoholism. Dr. Jentsch and colleagues at the University of California, Los Angeles, are studying genetic and neurochemical factors that influence individual differences in inhibitory control.
abril del 2012 New research establishes that benzodiazepines cause addiction in a way similar to that of opioids, cannabinoids, and the club drug GHB. The discovery opens the door to designing new benzodiazepines that counteract anxiety but are not addictive.